Rich Pipeline Delivers the Most Comprehensive End-to-End Solutions
for Next-Generation Sequencing
SAN DIEGO--(BUSINESS WIRE)--Jan. 8, 2013--
Illumina (NASDAQ: ILMN) today announced a series of product and
technology innovations for its powerful sequencing ecosystem – from
sample preparation to system enhancements to data analysis –– that will
enable the next breakthroughs in understanding the genome.
“Illumina has consistently led the market in conceptualizing,
developing, and executing on industry-changing sequencing technology,
and we continue to provide scientific advances that facilitate fully
integrated and highly economical sequencing with very rapid turnaround,”
said Jay Flatley, President and Chief Executive Officer of Illumina.
“These capabilities allow us to continue to meet the evolving needs of
our customers, as they develop an ever-increasing range of applications,
in new and emerging markets from agrigenomics to molecular diagnostics.”
Sample Prep Evolution
Simplifying and accelerating the sample prep process is fundamental to
improving sequencing workflows and decreasing turnaround time, an
important factor for sequencing to be adopted in clinical settings.
Illumina announced and previewed several innovations in sample
Nextera® Rapid Capture Exome Kits represent a new generation of
targeted enrichment products, providing the fastest exome enrichment
workflow on both the HiSeq® 2500 and the MiSeq®. With a sample-to-data
protocol of less than three days, the kits deliver a 70% speed
improvement over current technologies, with a solution optimized for
efficient enrichment of coding content. Commercial availability for
these kits is scheduled for the end of 1Q’13.
Nextera Rapid Capture Custom Kits enable enrichment of hundreds
of kilobases to tens of megabases of custom-selected content. Fully
automated probe design through DesignStudio™ and the ability to add
content to previously designed panels will be provided. Nextera Rapid
Capture Custom Kits will begin shipping in 2Q’13.
TruSeq® DNA PCR-Free Kits are a simple, all-inclusive sample
prep solution for whole-genome sequencing providing industry-best
genome coverage, the ability to sequence the most challenging regions,
and the power to identify variants with high accuracy. These kits will
be available to order on January 21, 2013.
Nextera Mate-Pair Sample Preparation Kits offer the only
gel-free method for preparing up to 15 kb mate-pair libraries in less
than two days with the industry’s lowest DNA input; an ideal approach
for de novo sequencing, genome finishing, and the detection of
structural variation – even in the most complex genomes such as those
derived from cancer. These kits are available for immediate order.
TruSeq Targeted RNA Kits bring a new standard to mid-plex gene
expression profiling and validation by overcoming significant
challenges in cost and workflow. User-defined custom panels of
12-1,000 assays can be created to target genes, isoforms, splice
junctions, and cSNPs, all of which can be added to a wide variety of
pre-selected gene panels focused on cell pathways and disease states.
Commercial availability for the TruSeq Targeted RNA Kit is scheduled
Core Technology Enhancements
Illumina also highlighted a number of core sequencing platform
enhancements that will increase the throughput, read lengths, and speed
of existing systems, as well as decrease running costs.
A new flow cell technology will provide a significant increase
in cluster density and number of reads per flow cell while reducing
image-processing time. This new technology improves support for
counting applications, lowers the cost per data point, and reduces
turnaround time for sequencing projects. First customer experience
with these new flow cells will occur in the second half of this year.
A novel library prep method and analysis algorithm, enabled by
the acquisition of Moleculo Inc., will produce synthetic read lengths
up to 10 kb at an extremely low error rate (Q50 or better). This
advancement allows more comprehensive coverage and accurate genotyping
of clinically important genes and new applications such as phased
resequencing of human genomes, and rapid de novo sequencing
of complex plant and animal genomes.
HiSeq 2500 chemistry enhancements empower the industry’s
highest daily throughput and drive down the price of whole-genome
sequencing. With support of paired 250 base pair read lengths in rapid
run mode, the HiSeq 2500 will be capable of generating up to 300 Gb in
rapid mode with sample to data in less than three days. These
enhancements will be available in the second half of this year.
Illumina also shared today a development in the evolution of its
cloud-based data analysis, storage, and sharing platform, BaseSpace™ (www.illumina.com/basespace):
BaseSpace Apps, a dedicated applications store for BaseSpace,
has quickly become a seminal environment for the deployment of
informatics tools. Today the community has grown to more than 100
independent developers who are working to bring a wide assortment of
analysis tools to a growing cloud-enabled user base.
“Our ability to rapidly innovate across the entire workflow of
next-generation sequencing ensures we are better positioned than ever to
continue creating and delivering value to both our research and clinical
customers,” said Christian Henry, Senior Vice President and General
Manager of Illumina’s Genomic Solutions business. “With enhancements to
our platform, we continue to set the standard for speed, accuracy,
output, and workflow.”
is a leading developer, manufacturer, and marketer of life science tools
and integrated systems for the analysis of genetic variation and
function. We provide innovative sequencing and array-based solutions for
genotyping, copy number variation analysis, methylation studies, gene
expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products
accelerate genetic analysis research and its application, paving the way
for molecular medicine and ultimately transforming healthcare.
This release contains forward looking statements that involve risks and
uncertainties. Examples of forward-looking statements include, but are
not limited to, statements we make regarding the expected shipping and
availability dates for new sample preparation products and technology
enhancements. Important factors that could cause actual results to
differ materially from those in any forward-looking statements include
challenges inherent in developing, manufacturing, and launching new
products and services and the other factors that are detailed in our
filings with the Securities and Exchange Commission, including our most
recent filings on Forms 10-K and 10-Q, or in information disclosed in
public conference calls, the date and time of which are released
beforehand. We do not intend to update any forward-looking statements
after the date of this release.
Source: Illumina, Inc.